ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers

Phase 1 Recruiting 16 enrolled National University Hospital, Singapore EDDC (Experimental Drug Development Centre), A*STAR Research Entities · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.

Timeline

Start: 2024-12-09
Primary completion: 2026-12-31
Completion: 2027-06-30

Publications

Results Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25.
Results DeVito NC, Sturdivant M, Thievanthiran B, Xiao C, Plebanek MP, Salama AKS, Beasley GM, Holtzhausen A, Novotny-Diermayr V, Strickler JH, Hanks BA. Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell Rep. 2021 May 4;35(5):109071. doi: 10.1016/j.celrep.2021.109071.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ETC-159	Small molecule	8 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	—	Intravenous
Background	Denosumab	Monoclonal antibody	—	Subcutaneous
Background	Zoledronic acid	Other / unclassified	—	Intravenous

Indications

No indication recorded.